WALTHAM, Mass.--Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €425 million aggregate principal amount of 1.50% senior notes due 2020 at an issue price of 99.971% of the principal amount. The issuance of the notes is expected to close on or about November 24, 2015, subject to customary closing conditions. The notes will pay interest on an annual basis.
The company plans to use a portion of the net proceeds of the offering to redeem all of the outstanding $400 million aggregate principal amount of 3.50% senior notes issued by Life Technologies Corporation prior to its acquisition by Thermo Fisher, which mature on January 15, 2016, and the remainder for general corporate purposes.
The joint book-running managers for the offering are Deutsche Bank AG, London Branch and HSBC Bank plc.
The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission (“SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling Deutsche Bank AG, London Branch toll-free at 1-800-503-4611, or by calling HSBC Bank plc toll-free at 1-866-811-8049.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the company’s intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and prospectus supplement dated November 13, 2015 related to the offering, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings,” and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
